Loading
A phase 1/2 trial of Belantamab mafodotin, Pomalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, now recruiting.
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments is a phase 1/2 interventional study registered as NCT05714839 by GlaxoSmithKline, with 123 participants planned, started 2023-06-14 and due to reach its primary completion in 2028-08-03. Interventions recorded: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
Shares Belantamab mafodotin, GSK, Multiple myeloma.
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Dexamethasone, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Dexamethasone, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/